All Stories

NextCure advances ADC pivot with $745M deal for Simcere's phase 1 drug

NextCure has ramped up its antibody-drug conjugate pivot, penning a $745 million deal for the ex-China rights to Simcere Zaiming’s phase 1-stage tumor asset.

Jun 16, 2025 - 16:20
 0
NextCure advances ADC pivot with $745M deal for Simcere's phase 1 drug
NextCure has ramped up its antibody-drug conjugate pivot, penning a $745 million deal for the ex-China rights to Simcere Zaiming’s phase 1-stage tumor asset.
Read More

Tags:

Previous Article

Gilead lays off 36 people after axing California expansion plan

Next Article

7ff: Revolutionizing Online Gaming with Innovation and Reliability

Related Posts

ASCO: J&J shares survival data on prostate cancer bispecific, furthering broad but solitary pursuit of KLK2

ASCO: J&J shares survival data on prostate cancer bispe...

Jun 2, 2025  0

Atsena eye disease gene therapy hits safety goals, closes retinal splits in phase 1/2

Atsena eye disease gene therapy hits safety goals, clos...

May 19, 2025  0

Pfizer CEO talks Chinese due diligence, ADC synergies to justify $6B bet on 'fabulous' bispecific

Pfizer CEO talks Chinese due diligence, ADC synergies t...

Jun 11, 2025  0